Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.

NCT06278857 is registered in ClinicalTrials.gov with Queensland Centre for Gynaecological Cancer as lead sponsor.

NCT NCT06278857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06278857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.
Lead sponsor
Queensland Centre for Gynaecological Cancer
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2024
Completion date
June 30, 2028
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer stage i, endometrioid endometrial adenocarcinoma, immune-related adverse event, mmr deficiency